JPRN-UMIN000021263Completed未知
ong-Term Outocomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice Settings - Orencia Registry in Geographically Assembled Multicenter Investigation Study
Bristol-Myers Squibb K.K. Ono Pharmaceutical CO.,LTD.0 sites325 target enrollmentStarted: March 1, 2016Last updated:
Conditions
Trial Snapshot
- Phase
- 未知
- Status
- Completed
- Sponsor
- Enrollment
- 325
Study Overview
Brief Summary
No summary available.
Study Design
- Study Type
- Observational
Eligibility Criteria
- Ages
- 20years-old to ot applicable (—)
- Sex
- All
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Patients will be excluded from the study if have 1) Past history of hypersensitivity to the components of the abatacept preparation 2) Complication of a malignant tumor 3) Active infectious disease 4) Hepatitis B and hepatitis B virus carrier (HBs antigen positive) 5) Pregnancy or lactating, or with the possibility of the pregnancy or lactating 6)Been judged by the investigator or the co-investigator as being inappropriate
Investigators
Similar Trials
Recruiting
Not Applicable
Abatacept Research Outcome as a First-line Biological Agent in the Real WorldRheumatoid ArthritisJPRN-UMIN000004651Division of Rheumatology Department of Internal Medicine, Hyogo College of Medicine100
Completed
Not Applicable
Long-Term Outcomes With Abatacept In Biologic Treatment-Naive Rheumatoid Arthritis Patients In Japanese Clinical Practice SettingsRheumatoid ArthritisNCT02758769Bristol-Myers Squibb303
Completed
Phase 2
Evaluation of safety and efficacy to abatacept treatment of patients with HBV-related acute liver failure.-Pilot StudyJPRN-UMIN000016148Hiroshima liver study group5
Completed
Not Applicable
Analysis of Effectiveness and Safety of Abatacept in Japanese patients with Rheumatoid Arthritis.Rheumatoid arthritisJPRN-UMIN000005144Tokyo Medical and Dental university300
Completed
Phase 2
Safety and Efficacy of abatacept (s.c.) in patients with CTLA4 insufficiency or LRBA deficiencyCTLA4 insufficiency or LRBA deficiencyD84.9Immunodeficiency, unspecifiedDRKS00017736niversitätsklinikum Freiburg vertreten durch den Leitenden Ärztlichen Direktor und die Kaufmännische Direktorin20